Articles tagged with Colorectal Cancer
A study found that while overall colorectal cancer rates are decreasing, the incidence of late-stage cancer in young patients is increasing. The study, which analyzed data from Colorado patients, reveals a significant rise in late-stage CRC diagnoses among those under 50.
A study found that genes involved in the Wnt signaling pathway are more frequently altered in younger patients with colorectal cancer. This pathway drives the growth and proliferation of cancer stem cells. The research suggests targeting this pathway may be a promising strategy for treating aggressive CRC in young patients
A free colonoscopy program for uninsured patients has been shown to detect cancer at an earlier stage and appears to be cost-neutral. The program, which was expanded to all hospitals in Louisville, is being hailed as a model for statewide implementation in Kentucky.
Researchers developed a new method of diagnosing colorectal cancer using 3D hydrogel biochips, which detect tumor-associated glycans and improve sensitivity. The study analyzed sera from 33 patients with colorectal cancer, 69 healthy donors, and 27 patients with inflammatory bowel disease.
A recent study published in The Lancet found that the global economic crisis was associated with an increase in cancer mortality, particularly among treatable cancers. Universal health care coverage may protect patients from the health consequences of rising unemployment and reduced public-sector healthcare spending.
A study using whole-exome sequencing has identified genomic alterations in both colorectal adenomas and at-risk mucosa, shedding light on the evolution of normal mucosa to precancer. The research provides a catalog of genomic changes preceding colorectal cancer development in patients with familial adenomatous polyposis.
Researchers found a significant increase in colorectal cancer cases under 50 years old, with advanced stages at diagnosis. The study suggests healthcare providers need to be more vigilant in detecting symptoms in younger patients.
Researchers identified 2,314 genetic changes in polyps and adjacent mucosa, revealing potential drug targets for colorectal cancer prevention. The study also found similarities between premalignant and cancerous tissue, suggesting that polyps with more genetic changes may be more likely to develop into CRC.
A Mayo Clinic study found that endoscopists with knowledge of a positive Cologuard test detected polyps or hemorrhagic lesions 83% of the time, compared to 68% without this information. This increased detection led to more true-positive results and fewer false-negative results.
Researchers used genetically-engineered mice to study the role of a Western-style diet in colon cancer development. They found that a low-fiber, high-fat diet increased the risk of colon cancer and identified key changes in gene expression profiles before tumor formation.
A new Kaiser Permanente study found that overweight colorectal cancer patients had a significantly lower risk of death from their cancer compared to normal-weight patients. The study analyzed data from over 3,400 patients and found that those who were in the high-overweight category at diagnosis had a 55% lower risk of mortality.
Researchers discovered an alternative pathway emerges when ERK1/2 is blocked, allowing tumor cell proliferation to continue. Targeting both ERK pathways concurrently with drug inhibitors halted colorectal cancer growth more effectively in mouse models and human cell lines.
Researchers have found that a specific blood marker is common among patients with a subset of metastatic colorectal cancer, increasing their chances of responding to the drug. This breakthrough builds on an international clinical trial and could lead to more effective treatment options for patients running out of time.
A new blood marker, FCGR2A, identifies patients with metastatic colorectal cancer who will benefit from the drug cetuximab. The discovery helps personalize cancer medicine for those with colorectal disease, improving treatment outcomes.
Research shows that 1 in 5 colorectal cancer patients are depressed at diagnosis, and this can significantly impact their quality of life. The study highlights the importance of considering psychological factors in patient care and support.
A new study links MS drug mitoxantrone to an increased risk of colorectal cancer, with patients treated with the medication being three times more likely to develop the disease. However, the overall rate of cancer was low enough that the researchers suggest continuing its use for severely affected patients.
A new study suggests that removing the ovaries may increase the risk of colorectal cancer in women. Among 195,973 Swedish women who underwent ovary removal between 1965 and 2011, a 30% higher rate of colorectal cancer was found compared to the general population. The risk was even higher for women who had both ovaries removed.
A large case-control study found that statin use is associated with a reduced risk of colorectal cancer, but the difference in risk between statin users and non-users was not significant. Increased serum cholesterol levels were also independently linked to decreased risk of colorectal cancer.
A large case-control study suggests that high cholesterol levels, rather than statin use, may influence the risk of colorectal cancer. The study found an inverse relationship between blood cholesterol levels and colorectal cancer risk, with higher cholesterol levels associated with lower risk.
The phase 1b clinical trial of atezolizumab has reported promising results in 23 patients with metastatic colorectal cancer. Fifty-two percent responded to treatment, and median progression-free survival was 14.1 months. Another patient, Rodney Bearfoot, has remained on the study for over three years despite a stage 4 diagnosis.
Researchers developed a risk prediction model integrating 19 environmental and lifestyle risk factors with 64 common genetic risk factors to identify individuals at high risk of developing colorectal cancer. The model aims to improve colonoscopies for those at higher risk, while avoiding unnecessary procedures for low-risk individuals.
A study found patients with flat adenomas are more likely to have large and advanced adenomas as well as multiple adenomas. This may require more frequent screenings for these patients. Colonoscopy is an effective screening test for colon cancer, allowing doctors to remove precancerous polyps.
Scientists have identified 182 genome instability suppressing (GIS) genes in yeast and over 400 previously unknown cooperating GIS genes. These findings suggest a complex genetic network maintaining genome integrity and highlight potential therapeutic targets for cancer treatment.
The USPSTF recommends taking low-dose aspirin for primary prevention of cardiovascular disease and colorectal cancer in adults aged 50-69 years with increased risk. Aspirin use can outweigh harms for some patients, including those at high risk for CVD, improving life expectancy and quality of life.
Researchers found that radiation treatment killed 95% of breast cancer cells when delivered during a peak in p53 production, but only 20% when applied during an oscillatory phase. The study suggests that timing may be crucial in understanding the effectiveness of anticancer treatments.
Regular low-dose aspirin use for at least six years was associated with a modestly reduced overall risk for cancer, primarily due to a lower risk for gastrointestinal tract cancer. The study found that regular aspirin use may complement CRC screening and have an absolute benefit regardless of endoscopy status.
The study found that regular aspirin use significantly reduces the overall risk of cancer, with a 19% lower risk of colorectal cancer. Aspirin may complement, but not replace, cancer screening methods like colonoscopy, and has potential benefits for individuals with risk factors.
Researchers found that patients with lung and colorectal cancer who had financial distress at diagnosis reported significantly increased pain, symptom burden, and poorer quality of life. The study highlights the need for clinicians to target resources and treatments for patients struggling financially.
A new Canadian guideline recommends fecal occult blood testing (FOBT) every two years or flexible sigmoidoscopy every 10 years for routine screening of colorectal cancer in asymptomatic, low-risk adults aged 50-74. The guideline also recommends against colonoscopy as a primary screening tool, citing lack of direct evidence.
The American Cancer Society report reveals progress in reducing cancer death rates among African-Americans, but racial disparities persist in breast and colorectal cancers. The study finds that disparities in access to care and screening contribute to these disparities.
Colorectal cancer patients require follow-up colonoscopy after surgery to detect second cancers and polyps, with recommended intervals varying from one to nine years. The US Multi-Society Task Force updates guidelines to emphasize the role of colonoscopy in post-surgical surveillance.
Research by Michigan Medicine found that nearly 15% of colorectal cancer patients were diagnosed before age 50, often with more advanced disease. Younger patients had better survival rates due to aggressive treatment, suggesting the need for improved long-term survivorship resources.
The American College of Physicians (ACP) offers guidance on evaluating blood in the urine, emphasizing the importance of referring patients with gross hematuria and confirming heme-positive results. For adults with microscopically confirmed hematuria, urology referral for cystoscopy and imaging is recommended.
A study of US data found that one in seven colorectal cancer patients is younger than 50 years old, often presenting with advanced stage disease. However, these patients tend to receive more aggressive therapy and have a slightly longer survival rate without recurrence.
A University of Colorado study found distinct genetic drivers in colorectal cancer among young and old patients, with potential implications for targeted therapies.
Research at Thomas Jefferson University reveals obesity is associated with a key hormone's absence, leading to tumor suppressor pathway deactivation and increased colorectal cancer risk. A therapeutic approach using the pill linaclotide, structurally related to the lost hormone, may prevent cancer in obese patients.
Seven scientists with novel approaches to fighting cancer have been named recipients of the Damon Runyon-Rachleff Innovation Award. The grant funds cancer research by exceptionally creative thinkers with 'high-risk/high-reward' ideas, aiming to significantly impact cancer prevention, diagnosis, and treatment.
A recent US study found that minority and ethnic groups are being diagnosed with colorectal cancer at younger ages than non-Hispanic whites. The study reveals that these groups have twice the risk of developing the disease before age 50, with advanced stages at diagnosis.
Researchers at University of Missouri-Columbia discovered that the gene Sprouty2, previously believed to suppress cancer growth, may actually promote metastasis in colorectal cancer. This finding has significant implications for understanding and treating the disease.
A new study by Sylvester researchers describes the immune system's response to tumor development, highlighting the stimulator of interferon genes (STING) signaling pathway's potential suppression of colorectal cancer. Impaired STING responses may enable damaged cells to evade the immune system.
A study published in JNCI Journal of the National Cancer Institute found that virtual colonoscopy had higher detection rates than traditional methods like FIT and OC. The researchers concluded that combination of lower attendance and higher detection rate makes CTC a key factor for optimization of its role in population screening.
A new American Cancer Society study reveals that excess medical expenditures and productivity losses vary significantly among cancer survivors by age and cancer site. Nonelderly survivors of colorectal and breast cancers experience higher annual expenditures compared to those without a cancer history.
A study published in JAMA found that nearly half of working individuals with stage III colorectal cancer lost their jobs due to their diagnosis. However, those with access to paid sick leave were more likely to retain their jobs and experience reduced personal financial burdens. The study highlights the importance of providing paid sic...
A new study reveals that Latinos from Mexico have the lowest chance of getting colorectal cancer, while those from Central or South America are diagnosed with the disease before age 50 at a higher rate. The research aims to pave the way for personalized cancer care and reduce disparities in treatment
Scientists have mapped out the human genome to identify essential genes for cell survival, revealing a core set of over 1,500 genes. The findings suggest that each tumor relies on a unique set of genes that can be targeted by specific drugs, offering hope for devising new treatments.
A city-wide initiative in NYC increased colorectal cancer screening colonoscopy rates from 42% to 62% and eliminated disparities based on race/ethnicity. The program included public education, outreach to healthcare providers, and culturally tailored campaigns to boost awareness and overcome hurdles to effective screening.
A city-wide coalition launched by NYC DOHMH and Mount Sinai resulted in a 40% increase in colorectal cancer screening rates over four years. Screening rates rose from 42% in 2003 to 62% in 2007, with significant reductions in disparities based on ethnicity.
A study at MD Anderson Cancer Center reveals that increased methylation of epidermal growth factor receptors (EGFR) leads to resistance to cetuximab antibody therapy, resulting in poorer clinical outcomes and higher recurrence rates. The study also found that expression of methylation-defective EGFR reduces tumor growth in mice.
A study by CDC found that poorer communities bear the greatest economic burden due to colorectal cancer deaths. The researchers estimated $4.2 billion in productivity gains if eliminateable deaths are avoided.
A new stool DNA test has been found accurate in screening for colorectal cancer among Alaska Native people, a population with one of the world's highest rates of the disease. The test detected significantly more screen-relevant neoplasms than traditional fecal occult blood testing methods.
Researchers have identified a small RNA molecule, SNORA42, that enables aggressive colorectal cancers to progress and resist treatment. Detecting high levels of this biomarker in patient tissues may help clinicians determine which patients benefit from more aggressive therapy.
Researchers found no significant difference in new polyp formation between patients with vitamin D and/or calcium supplements and those without. The study's results contradict previous findings in models and smaller human trials, highlighting the need for further research on promising cancer prevention strategies.
A University of Colorado Cancer Center study found TAK-733 to be highly active against colorectal cancer cells and tumors, with 42 of 54 cell lines sensitive to the drug. However, inconsistent absorption and bioavailability were observed, raising concerns about safety and tolerability.
A study by the University of Melbourne found a significant disparity in bowel cancer deaths between European men and women. Lifestyle factors such as diet, smoking, and alcohol consumption are linked to higher rates of bowel cancer in men. The researchers suggest that countries with high levels of screening have seen substantial reduct...
A study published in The BMJ reveals significant disparities in bowel cancer mortality rates across Europe, with notable variations between men and women and different regions. Colorectal cancer mortality has decreased in many European countries over the past two decades, but important differences remain.
A study published in Clinical Gastroenterology and Hepatology suggests that all relatives of individuals with colorectal cancer are at increased risk for this cancer, regardless of their age. The risk is highest among young first-degree relatives under 50 years old.
A researcher is calling for updated guidelines on colorectal cancer screening, citing evidence that most patients with a family history of the disease can stop aggressive screening at age 65. The study found that the risk of colorectal cancer diagnosis decreases with increasing age in patients with a family history.
A study based on over 10 million patients found that family health teams led to improved diabetes monitoring and screening rates. Patients in these teams were more likely to receive recommended testing and screenings for breast cancer and colorectal cancer.
Researchers at Nanjing University have discovered new epigenetic markers for colorectal cancer, which may offer a new approach for treatment. The study found that heterochromatin protein HP1γ was critical for CRC cell proliferation and could be specially regulated by miR-30a.
A study found that examining the right side of the colon while patients lie on their left side increases polyp and adenoma detection. This position change also improved distension of the colon, allowing for better visualization. The results suggest a more effective tool for ongoing surveillance and prevention.